DK1993585T3 - Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme - Google Patents

Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme

Info

Publication number
DK1993585T3
DK1993585T3 DK07712377.6T DK07712377T DK1993585T3 DK 1993585 T3 DK1993585 T3 DK 1993585T3 DK 07712377 T DK07712377 T DK 07712377T DK 1993585 T3 DK1993585 T3 DK 1993585T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
viral diseases
long pentraxin
pentraxin ptx3
Prior art date
Application number
DK07712377.6T
Other languages
English (en)
Inventor
Paolo Carminati
Marica Sassano
Francesco Bistoni
Luigina Romani
Silvia Bozza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of DK1993585T3 publication Critical patent/DK1993585T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK07712377.6T 2006-03-10 2007-02-28 Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme DK1993585T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06004971A EP1832295A1 (en) 2006-03-10 2006-03-10 Use of PTX3 for the treatment of viral diseases
PCT/EP2007/051889 WO2007104646A2 (en) 2006-03-10 2007-02-28 Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases

Publications (1)

Publication Number Publication Date
DK1993585T3 true DK1993585T3 (da) 2014-07-07

Family

ID=37057312

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07712377.6T DK1993585T3 (da) 2006-03-10 2007-02-28 Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme

Country Status (16)

Country Link
US (2) US7910092B2 (da)
EP (2) EP1832295A1 (da)
JP (1) JP5190605B2 (da)
KR (1) KR101477781B1 (da)
CN (2) CN102657844B (da)
AU (1) AU2007224564B2 (da)
CA (1) CA2646419C (da)
CY (1) CY1115194T1 (da)
DK (1) DK1993585T3 (da)
ES (1) ES2475729T3 (da)
HK (2) HK1129301A1 (da)
MX (1) MX2008011413A (da)
PL (1) PL1993585T3 (da)
PT (1) PT1993585E (da)
SI (1) SI1993585T1 (da)
WO (1) WO2007104646A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
WO2011012496A1 (en) 2009-07-29 2011-02-03 Tecnogen S.P.A. Improved human long pentraxin 3 expression system and uses thereof
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
WO2021230233A1 (ja) * 2020-05-14 2021-11-18 学校法人日本医科大学 感染症の治療又は予防剤
CN114369150B (zh) * 2022-01-24 2023-10-31 上海市儿科医学研究所 Mptx2蛋白及其治疗耐甲氧西林金黄色葡萄球菌感染相关病症的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (da) * 1991-09-13 1994-05-21 Paul B Chretien
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
CA2270223A1 (en) 1996-10-28 1998-05-07 Carson B. Burgstiner (Deceased) Methods and compositions for dietary supplementation
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ITRM20010294A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
US20040137544A1 (en) * 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection

Also Published As

Publication number Publication date
HK1129301A1 (en) 2009-11-27
WO2007104646A3 (en) 2007-11-15
US7910092B2 (en) 2011-03-22
KR20080104059A (ko) 2008-11-28
EP1832295A1 (en) 2007-09-12
PT1993585E (pt) 2014-07-11
WO2007104646A2 (en) 2007-09-20
CA2646419C (en) 2014-10-14
CN102657844B (zh) 2014-03-26
KR101477781B1 (ko) 2014-12-30
US20090286726A1 (en) 2009-11-19
AU2007224564A1 (en) 2007-09-20
EP1993585B1 (en) 2014-04-09
HK1173983A1 (en) 2013-05-31
PL1993585T3 (pl) 2014-09-30
CN102657844A (zh) 2012-09-12
JP5190605B2 (ja) 2013-04-24
CN101426516B (zh) 2012-05-30
SI1993585T1 (sl) 2014-08-29
MX2008011413A (es) 2008-12-15
CA2646419A1 (en) 2007-09-20
AU2007224564B2 (en) 2011-09-29
US8268304B2 (en) 2012-09-18
JP2009529563A (ja) 2009-08-20
CN101426516A (zh) 2009-05-06
US20110224132A1 (en) 2011-09-15
CY1115194T1 (el) 2017-01-04
ES2475729T3 (es) 2014-07-11
EP1993585A2 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
DK2139517T3 (da) Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
DK2220076T5 (da) Inhibitorer af replikationen af humant immundefektvirus
DK1984357T3 (da) 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK2040713T3 (da) Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DE602006016150D1 (de) Vorbeugung von krankheiten bei kaiserschnitt-babies
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
DK2146732T3 (da) Fremgangsmåder til behandling eller forebyggelse af emese ved hjælp af væksthormonsekretagoger
DK1865976T3 (da) Anvendelse af natriuretiske peptider til behandling af hjertesvigt
DK1771201T3 (da) Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
BRPI0811016A2 (pt) Proteína li truncada do papiloma vírus humano tipo 16
DK1948176T3 (da) Diarylurinstoffer til behandling af pulmonær hypertension
DK1993585T3 (da) Anvendelse af den lange pentraxin PTX3 til forebyggelse eller behandling af virussygdomme
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
DK1962869T3 (da) Behandling af luftvejssygdomme
DK1835907T3 (da) Lægemidler til behandling eller forebyggelse af fibrotiske sygdomme
DK1846354T3 (da) Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande